Midatech Pharma (NASDAQ:MTP) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a report released on Wednesday.
Shares of Midatech Pharma stock traded down $0.04 during midday trading on Wednesday, hitting $0.81. The company had a trading volume of 165,007 shares, compared to its average volume of 185,693. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.11 and a current ratio of 2.22. Midatech Pharma has a 52-week low of $0.71 and a 52-week high of $3.27.
Midatech Pharma Company Profile
Midatech Pharma PLC, a specialty pharmaceutical company, focuses on the development and commercialization of oncology and other therapeutic products in the United Kingdom, Turkey, other European countries, and the United States. It offers Oravig, an orally dissolving buccal tablet for oral thrush and oropharyngeal candidiasis in adults; Gelclair, an oral rinse gel for the management and relief of pain arising from oral lesions of various etiologies; Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; and Soltamox, an oral liquid solution of tamoxifen citrate for the prevention of breast cancer.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Midatech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.